Sign in

CIK 0001782223

  • Emerging growth company

Pyxis Oncology, Inc.

Sign in to watch
Ticker
PYXS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
831160910
Phone
+1 617-221-9059
Business address
321 HARRISON AVENUE, BOSTON, MA, 02118
Open-market buys, last 90 days
$0
in 1 filing
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2026-03-24 Wadhane Jitendra Prin Fin & Acct Officer Grant or award +109,461 512,882
2026-03-24 Wadhane Jitendra Prin Fin & Acct Officer Grant or award · Stock Option (Right to Buy) +262,635 262,635
2025-03-31 Wadhane Jitendra SVP, Chief Accounting Officer Grant or award · Stock Option (Right to Buy) +263,782 $0.98 $259K 263,782
2024-12-23 Wadhane Jitendra SVP, Chief Accounting Officer Grant or award · Stock Option (Right to Buy) +150,000 150,000
2024-03-26 Wadhane Jitendra SVP, Chief Accounting Officer Grant or award +131,484 398,421
2023-11-15 Wadhane Jitendra Chief Accounting Officer Grant or award +40,000 266,937
2023-09-27 Wadhane Jitendra Chief Accounting Officer Purchase +2,500 $1.87 $5K 226,937
2023-09-25 Wadhane Jitendra Chief Accounting Officer Purchase +5,000 $1.77 $9K 224,437
2023-09-22 Wadhane Jitendra Chief Accounting Officer Purchase +2,500 $1.74 $4K 219,437
2023-09-07 Wadhane Jitendra Chief Accounting Officer Grant or award +93,896 211,937
2023-03-24 Wadhane Jitendra Chief Accounting Officer Grant or award +29,393 118,041
2023-03-24 Wadhane Jitendra Chief Accounting Officer Grant or award +45,000 88,648
2023-03-24 Wadhane Jitendra Chief Accounting Officer Returned to the company · Stock Option (Right to buy) −157,257 0
2023-03-24 Wadhane Jitendra Chief Accounting Officer Grant or award · Stock Option (Right to buy) +157,257 157,257

Page 1 of 1 · 14 trades